2014 CME Symposia - Breakfast Symposium B
Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!
Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.
Breakfast Symposium B
Friday · 6:15 - 7:45am
Innovations in GLP-1 Receptor Agonist Therapy:
Individualized Treatment Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in Type 2 Diabetes Mellitus
Supported by an educational grant from Lilly USA, LLC
Some of the newer type 2 diabetes therapies, including GLP-1 receptor agonists, do not carry the same limitations as traditional therapies. This class of drugs has been shown to improve global cardiometabolic risk factors and to improve the function of beta cells, rather than just address hyperglycemia. Our faculty will help clinicians understand the differences between GLP-1 receptor agonists, not only in terms of their mechanisms of action, but in terms of their impact on glucose control, beta cell function, and cardiovascular risk factors such as body weight, blood pressure, and lipid profiles. A review of current guideline recommendations will help clinicians appropriately integrate this class of medications into clinical practice to improve outcomes in the management of type 2 diabetes.
- Overcome common barriers to patient acceptance of and adherence to T2DM therapies by individualizing treatment strategies, minimizing adverse events and side effects, and increasing patient satisfaction.
- Discuss the physical structure and pharmacokinetic/pharmacodynamic data for available and emerging short-acting and long-acting GLP-1 receptor agonist therapies and discuss how each agent differs in terms of its effects on HbA1c, fasting and post-prandial glucose, non-glycemic parameters, and safety/tolerability.
- Cite the effects of GLP-1 receptor agonists on cardiovascular risk factors such as body weight, blood pressure, and lipid profiles.
- Identify patients most likely to benefit from GLP-1 receptor agonist therapy, based on patient characteristics such as comorbidities, co-medications, and attitudes toward injections, and individualized guideline-based treatment regimens.
Preliminary Agenda & Faculty
|6:15 - 6:20am
||Chairperson: John B. Buse, MD, PhD
|6:20 - 6:35am
||Clinical Practice Guidelines for Managing Patients with Type 2 Diabetes: Where do Incretins Fit into the Treatment Paradigm?
||Presenter: John B. Buse, MD, PhD
|6:35 - 7:00am
||GLP-1 Receptor Agonists: Similarities and Differences
||Presenter: Richard E. Pratley, MD
|7:00 - 7:20am
||The Role of GLP-1 Receptor Agonists in Overcoming Common Patient Treatment Barriers
||Presenter: Samuel Dagogo-Jack, MD
||Improving and Addressing Cardiometabolic Risk with GLP-1 Receptor Agonists
||Moderator: John B. Buse, MD, PhD
Presenters & discussants: Samuel Dagogo-Jack, MD; Richard E. Pratley, MD
Richard E. Pratley, MD
- Director, Florida Hospital Diabetes Institute
- Senior Scientist, Translational Research Institute
for Metabolism and Diabetes
- Professor, Sanford Burnham Medical Research Institute
- Winter Park, FL
Samuel Dagogo-Jack, MD
- Professor of Medicine
- Director, Div. of Endocrinology, Diabetes & Metabolism
- A. C. Mullins Chair in Translational Research
- Director, General Clinical Research Center
- Director, Endocrinology Fellowship Training Program
- University of Tennessee Health Science Center
- Memphis, TN
John B. Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, NC
View Complete Accreditation Details and Program Overview: CMHC Accreditation